

Noninvasive Total Cholesterol Level Measurement Using an E-Nose System and Machine Learning on Exhaled Breath Samples

Published as part of ACS Sensors special issue "Breath Sensing".

Anna Paleczek,* Justyna Grochala, Dominik Grochala, Jakub Słowik, Małgorzata Pihut, Jolanta E. Loster, and Artur Rydosz



Cite This: *ACS Sens.* 2024, 9, 6630–6637



Read Online


ACCESS |

Metrics & More

Article Recommendations

ABSTRACT: In this paper, the first e-nose system coupled with machine learning algorithm for noninvasive measurement of total cholesterol level based on exhaled air sample was proposed. The study was conducted with the participation of 151 people, from whom a breath sample was collected, and the level of total cholesterol was measured. The breath sample was examined using e-nose and gas sensors, such as TGS1820, TGS2620, TGS2600, MQ3, Semeatech 7e4 NO₂ and 7e4 H₂S, SGX_NO₂, SGX_H₂S, K33, AL-03P, and AL-03S. The LGBMRegressor algorithm was used to predict cholesterol level based on the breath sample. Machine learning algorithms were developed for the entire measurement range and for the norm range ≤ 200 mg/dL achieving MAPE 13.7% and 8%, respectively. The results show that it is possible to develop a noninvasive device to measure total cholesterol level from breath.

KEYWORDS: E-nose system, exhaled breath analysis, gas sensors, LGBMRegressor, machine learning, noninvasive measurement, predictive modeling, total cholesterol level



VOLATILE ORGANIC COMPOUNDS

In recent times, researchers have been working to develop noninvasive methods for measuring and monitoring health parameters, such as blood glucose levels,^{1–4} detection of FeNO for asthma and other respiratory diseases,^{5,6} SIBO (small intestine bacterial overgrowth), or various types of cancers.^{7–9} One possibility is to monitor exhaled breath and the volatile organic compounds (VOCs) contained in it. Human breath (Figure 1) consists mainly of nitrogen (78%–79%), oxygen (13%–16%), and carbon dioxide (4%).¹⁰ The rest of the parts are mostly VOCs. Currently, over 3,000 different VOCs have been identified in breath.¹¹ Some of them may be of endogenous origin and may be biomarkers of various diseases or conditions of the human body and come from metabolic processes occurring in the body. Exogenous VOCs are the result of external factors, such as smoking, air pollution, or drug metabolism.¹² The relative humidity of human breath is 89%–97%.¹³

CLINICAL IMPORTANCE OF MONITORING BLOOD CHOLESTEROL LEVELS

Cholesterol performs an essential role in human metabolism and permits homeostatic regulation. It is a crucial component of every cell membrane.¹⁴ As a steroid hormones' precursor,




Figure 1. Composition of inhaled and exhaled air.

Received: August 21, 2024

Revised: October 30, 2024

Accepted: November 6, 2024

Published: November 22, 2024



cholesterol is responsible for various immune, development and reproductive processes as well as mineral metabolism.¹⁵ Despite this biological significance, hypercholesterolemia contributes to the pathogenesis of cardiovascular diseases (CVDs)—a leading cause of death worldwide. According to the WHO 17.9 million people die of CVDs every year.¹⁶ Cholesterol can accumulate in the walls of arteries and form atheromatous plaques. After long asymptomatic period, plaque can rupture causing intravascular coagulation and ischemia. This phenomenon occurs particularly within the coronary, cerebral, and peripheral circulation, leading respectively to myocardial infarction, stroke, and limb ischemia. It is estimated that up to 90% of CVDs could be avoided by modifying risk factors.¹⁷ Hypercholesterolemia is one of the most important modifiable risk factors for CVDs, so regular assessment of cholesterol levels and early implementation of appropriate treatment are valuable for patients. Although the clinical use of total cholesterol (TC) in relation to the LDL-cholesterol (LDL-C) is very limited, a linear correlation of TC levels with cardiovascular risk has been demonstrated.¹⁸

THE RELATIONSHIP BETWEEN BLOOD CHOLESTEROL AND VOCS

It is presumed that isoprene is formed during cholesterol biosynthesis in nucleated cells by nonenzymatic conversion of DMAPP. Thereafter, it enters the alveoli via the vascular system and is excreted with exhaled air. The metabolic pathway of cholesterol and its relationship to isoprene in breath^{19–22} is shown in Figure 2.




Figure 2. Metabolic pathway of cholesterol and its relationship to isoprene in breath.

GAS SENSING METHODS

VOCS in breath occur in concentrations of parts per million (ppm), parts per billion (ppb), or even parts per trillion (ppt); therefore, determining their concentration in exhaled air is difficult using the commercially available gas sensors. There are reference methods, such as gas chromatography coupled with mass spectrometry,^{23,24} selected ion flow-tube mass spectrometry,²⁵ proton-transfer-reaction time-of-flight mass spectrometry,²⁶ which allow for the separation of gas mixtures into components and their quantitative analysis. The operation of such devices is complicated, they require special storage or long-term start-up procedures, and they are very expensive. Therefore, gas sensors for detecting low concentrations of compounds in gas mixtures have been widely developed. Because sensors can

detect multiple substances and exhaled air contains numerous volatile organic compounds, employing a matrix of gas sensors and machine learning algorithms is essential to increase the sensitivity and selectivity of the e-nose systems.

BREATH SAMPLING METHODS

Most often, breath is collected in bags specially designed for this purpose, which maintain the initial concentration of compounds contained in the gas mixture for up to several days.^{27–29} Such bags include Tedlar Bag, FlexFoil PLUS.³⁰ It is also possible to supply exhaled air directly to the device.^{31,32} Currently, there is no standardized method for storing and collecting breath samples, which leads to problems with reproducing studies and comparing results with those of other researchers.

RELATED WORKS

In the related literature, the study of exhaled isoprene and its relationship with cholesterol concentration is often mentioned, but no studies using e-nose to estimate cholesterol from exhaled breath have been presented yet. Gouma et al. proposed a selective nanosensor for exhaled breath analysis, which can be used for noninvasive monitoring of cholesterol levels. They developed sensor arrays for measuring isoprene, carbon dioxide and ammonia gas, however the sensor was tested only on synthetic gases that were composed to mimic human exhaled air.³³ Similar research was conducted by Güntner et al., who developed a Ti-doped ZnO sensor for selective sensing of isoprene for breath diagnosis. This sensor showed a significantly higher response to isoprene than to acetone, ammonia, or ethanol at 90% RH, which is the observed RH of human breath. In this case the authors also tested the sensor only on synthetic gas mixtures.³⁴

This paper introduces the first e-nose system combined with a machine learning algorithm for noninvasive measurement of total cholesterol levels using exhaled air samples. The study involved 151 participants from whom a breath sample was collected, and the level of total cholesterol was measured.

EXPERIMENTAL SECTION

Information About the Study Involving Human Participants. In collaboration with the Department of Prosthodontics and Orthodontics at the Dental Institute, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland, tests were conducted on breath samples and capillary blood samples collected from 151 individuals (Jagiellonian University bioethical committee approval KBET: 1072.6120.40.2023). The study included patients over the age of 45 to identify those at risk of developing features of metabolic syndrome.

Patients' Information. Each of the 151 participants completed a questionnaire that included questions about gender, weight, height, age, medications taken, past and current illnesses, and well-being related to the use of dentures and dental cavities. 92 women and 59 men participated in the study. Descriptive statistics of the sample population including data on participants' age, height, weight, and BMI are included in Table 1.

Table 1. Descriptive Statistics of the Sample Population

Parameter	Mean	Standard Deviation
Age	67	9.3
Weight	77 [kg]	15.5 [kg]
Height	166 [cm]	9.4 [cm]
BMI	27.7 [kg/m ²]	4.11 [kg/m ²]

Capillary Blood Tests. Participants in the study had their capillary blood samples analyzed by a physician using devices that measure parameters via the strip technique, such as

- Glucose (Accu-Chek Instant, Roche Diabetes Care GmbH, Sandhofer Strasse 116, 68305 Mannheim; www.roche.com).
- Uric acid (PEMPA 3in1 device, General Life Biotechnology Co., Ltd. 5F., No. 240, Shinshu Rd., Shin Juang Dist., New Taipei City 242, Taiwan; www.BeneCheck.com.tw).
- Cholesterol (PEMPA 3in1 device, General Life Biotechnology Co., Ltd. 5F., No. 240, Shinshu Rd., Shin Juang Dist., New Taipei City 242, Taiwan; www.BeneCheck.com.tw).
- Triglycerides (Accutrend Plus, Accutrend Glucose, Roche Diagnostics GmbH, Sandhofer Strasse 116, 68305 Mannheim; www.roche.com).

Descriptive statistics of blood test parameters, including data on measured values of glucose, uric acid, cholesterol, and triglycerides from capillary blood of the participants, are included in Table 2.

Table 2. Descriptive Statistics of Blood Test Parameters

Parameter	Mean	Standard Deviation
Glucose	110.5 [mg/dL]	31.32 [mg/dL]
Uric acid	5.66 [mg/dL]	1.49 [mg/dL]
Cholesterol	174.33 [mg/dL]	39.02 [mg/dL]
Triglycerides	124.5 [mg/dL]	84.53 [mg/dL]

Cholesterol Levels Distribution. In this paper, we focus on predicting cholesterol levels based on exhaled air measurements. The PEMPA 3-in-1 device allows cholesterol to be measured from fresh capillary blood in the range of 100–400 mg/dL (2.59–10.35 mmol/L). With this test, the norm is a result of ≤ 200 mg/dL (5.17 mmol/L).³⁵ The distribution of cholesterol values measured in the study participants is presented in Figure 3.




Figure 3. Distribution of cholesterol levels among the study participants.

Breath Tests. Breath samples were collected in Tedlar bags and analyzed using an electronic nose (e-nose) twice. Tedlar bags are specialized bags for collecting and storing breath samples. Their advantage is maintaining high concentrations of the collected substances, which allows the bags to be transported to the external laboratory and to cooperate with remote research centers or hospitals.^{28,36–38} However, the e-nose system that we propose is portable and allows for quick testing of the sample in a hospital or medical center (Figure 4).

E-Nose System. The e-nose comprised a system for pumping air from the bags and a set of sensors, including TGS1820, TGS2620, and TGS2600 (Figaro Engineering Inc., Mino, Osaka, Japan), MQ3



Figure 4. E-nose system used during measurements.

(Winsen, ZhengZhou, HeNan, China), 7e4 NO₂, 7e4 H₂S (SemeaTech, Los Angeles, USA and Shanghai, China), SGX_NO₂, SGX_H₂S (SGX SENSORTECH, Switzerland), K33 (Senseair, Delsbo, Sweden), and AL-03P, AL-03S (MGK SENSOR Co., Ltd., Saitama, Japan).

Sensors' Responses. As part of the study, the breath sample collected from each patient in a Tedlar bag was measured twice using the prepared e-nose system. The time of rinsing with ambient air collected through the filter was 10 min between subsequent measurements, and the time of air injection from the bag was 15 min. For each measurement, the R_A (sensor response to purge gas) and R_G (sensor response to breath sample) values were determined (as shown in Figure 5) and the responses of the S and S_1 sensors were calculated (eqs 1 and 2).

$$S = R_G - R_A \quad (1)$$

$$S = \frac{R_G}{R_A} \quad (2)$$

Gas sensor data typically consist of electrical values affected by measurement errors, noise, or drift^{39,40} due to changes in sensor layer properties. These quality issues can impact model training and performance, so researchers use signal processing techniques like




Figure 5. Stages of the breath sample measurement using the developed e-nose system.

filtering^{41,42} and baseline normalization,^{39,43,44} to prepare the data for next steps in the processing pipeline. In our solution, we used a mean filter⁴¹ to reduce noise, calculating an average of 10 samples, while calculating the sensor response (eqs 1 and 2), which takes into account the baseline value (in the sensor response in the purge stage), allows to minimize the influence of drift. Additionally, before testing using human breaths, the sensors were tested on synthetic mixtures and results were published in our previous papers.^{43,45}

Outliers Handling. Based on the sensor responses, four outliers were removed for the K33 (CO₂ sensor) and AL-03P (ethanol sensor) sensors. Measurements were removed where the K33 sensor measured a CO₂ value lower than 2%, which means that the breath sample was incorrectly collected, and measurements where the AL-03P sensor indicated a response indicating the presence of ethanol in exhaled air, which could come from the mouthwash.

Train Test Split. The data set was divided into training and test sets in a ratio of 90:10 so that both measured values of the breath sample of one patient were located in only one of the sets. The training set included breath sample measurements collected from 136 patients, and the test set included 15 patients. This means that when two measurements from each patient were used, the training and test sets included 272 and 30 samples, respectively.

Machine Learning Algorithms. The aim of the study was to develop an algorithm that would allow prediction of cholesterol concentration in blood using e-nose and breath sample. The R_G , S , and S_1 data from sensors available in e-nose and BMI were taken as features. For this purpose, machine learning algorithms were used for the regression problem. The study tested machine learning algorithms: linear regression, lasso regression, ridge regression, random forest, LGBM regressor, XGB regressor, CatBoost regressor, KNN regressor, and neural networks. The results for all algorithms were compared (Table 3) and the best results were obtained using

Table 3. Comparison of Machine Learning Algorithm Performance (Measured as Mean Absolute Error) in Total Cholesterol Level Prediction (Norm Range)

Algorithm	Mean absolute error
Linear Regression	17.02
Lasso Regression	20.82
Ridge Regression	16.43
Random Forest	17.11
LightGBM Regressor	12.94
XGBoost Regressor	19.41
CatBoost Regressor	16.84
KNN Regressor	19.11

LGBM regressor. For each algorithm, the hyperparameter space for searching was determined. The best hyperparameters were determined using the RandomSearchCV^{46,47} method from the scikit-learn library (30 splits, negative mean absolute error optimization)

LightGBM Regressor Model. LightGBM is a gradient boosting framework that employs tree-based learning algorithms designed for distribution and efficiency. It offers several key benefits including faster training speed, higher efficiency, and lower memory usage. Additionally, it provides better accuracy and supports parallel, distributed, and GPU-based learning, making it capable of handling large-scale data sets effectively.⁴⁸ Linear regression models, lasso, and ridge, assume linear relationships between variables, which is a major limitation in the case of sensors' data processing. LGBM, like random forest, CatBoost, and XGBRegressor, is a tree model that can better handle nonlinear relationships in the data.⁴⁹ LightGBM handles large numbers of features very well, which can lead to more accurate predictions, even when other models may struggle to maintain performance. LightGBM has parameters that allow for overfitting control (e.g., max_depth, num_leaves, and feature_fraction). This makes it easy to tune to generalize well to the data, which is an

advantage oversimpler models, such as linear regression, that have limited overfitting control. Additionally, LGBMRegressor has built-in function for feature importance calculation and analysis.⁵⁰

Metrics. The following metrics were used to evaluate the effectiveness of regression algorithms: mean absolute error (MAE), root-mean-square error (RMSE), mean absolute percentage error (MAPE), and R^2 coefficient.

RESULTS AND DISCUSSION

Cholesterol Level Distribution Analysis. The distribution of measured cholesterol levels in the patients is previously shown in Figure 3. The analysis of the histogram and the values of mean (174.33), median (166.0), and calculated skewness index (1.18) shows that the distribution of cholesterol level among the patients participating in the study is right-skewed (the skewness coefficient is greater than 0 and the mean is greater than the median). Twenty-six patients had a score above 200 mg/dL (norm result) and only 7 above 260 mg/dL.

Considering the aforementioned problem, we decided to train two separate algorithms.

Prediction of cholesterol level in the entire range.

Prediction of cholesterol level within the norm (≤ 200 mg/dL).

Additionally, the predicted value logarithm technique was used to limit the influence of skewness.⁵¹ For prediction over the full range, we obtained better results using only one measurement for each patient. The results for both cases are compared in Table 4.

Table 4. Comparison of Metrics for the Entire Range and Norm Range Prediction using LGBM Regressor

Metric	Entire range	Norm range
MAE	21.2	12.9
RMSE	26.4	15.8
R^2	0.22	0.52
MAPE	13.7%	8%

Prediction of Cholesterol Level in the Entire Range.

On average, the predicted cholesterol levels deviate from the actual values by about 21.22 mg/dL. The R -squared value indicates how well the model explains the variance in the target variable. An R^2 of 0.224 means that the model explains about 22.4% of the variance in cholesterol levels, which is relatively low. A MAPE of 13.73% means that, on average, the model's predictions are about 13.73% off from the actual cholesterol levels. A comparison of the values predicted by the machine learning algorithm based on breath sample testing and the values measured using the test strip and capillary blood is shown in Figure 6.

Prediction of Cholesterol Level within the Norm. The performance metrics obtained from the prediction model for total cholesterol levels in the norm range based on exhaled air are indicative of a quite successful model. On average, the predicted cholesterol levels deviate from the actual values by approximately 12.94 mg/dL. This RMSE value indicates that the typical prediction error is around 15.79 mg/dL, providing a more substantial penalty for larger errors. The R -squared (R^2) value of 0.522 signifies that the model explains about 52.2% of the variance in the cholesterol levels, which is moderately good but also highlights that there is room for improvement. Additionally, the model's predictions are, on average, within




Figure 6. Results of prediction of the total cholesterol level in the entire range.

7.99% of the actual values. These results suggest that while the model has a reasonable predictive capability, further refinement, additional features, and additional data could enhance its accuracy and reliability. A comparison of the values predicted (in norm range) by the LGBMRegressor algorithm based on breath sample testing and the values measured using the test strip and capillary blood is shown in Figure 7.




Figure 7. Results of prediction of the total cholesterol level in the norm range.

The Bland–Altman plot analysis provides further insight into the agreement between the predicted and actual total cholesterol levels. The mean difference (or bias) between the predictions and the actual measurements is 2.42 mg/dL. This small mean difference indicates that, on average, the model slightly overestimates the cholesterol levels by 2.42 mg/dL. The limits of agreement (LOA) are defined as the mean difference plus and minus 1.96 times the standard deviation of the differences. The upper LOA is 33.00 mg/dL, and the lower LOA is -28.15 mg/dL. This range suggests that 95% of the differences between the predicted and actual cholesterol levels fall within this interval. The Bland–Altman plot is illustrated in Figure 8.

Features Importance. Analysis of the most important features showed that the most important for prediction were the responses of the TGS1820, AL-03P, TGS2620, and MQ3 sensors. These are mainly sensors for acetone, ethanol, and

VOCs. Isoprene, which is most often observed as a cholesterol biomarker in breath, is also a volatile organic compound and can be detected by semiconductor sensors, such as TGS1820 or TGS2620. Gas sensors, especially those based on metal oxides (e.g., SnO_2), operate on the principle of electrical conductivity change in the presence of volatile organic compounds. Isoprene, being a VOC, can cause a change in conductivity similar to that of acetone or ethanol. Due to the cross-selectivity of sensors and the large number of VOCs in exhaled air, it is necessary to use a gas sensor matrix and machine learning algorithms.

CONCLUSIONS

In this paper, we proposed the first e-nose for prediction of total cholesterol concentration in blood based on the exhaled breath analysis. Machine learning algorithms were developed for the entire measurement range and for the norm range ≤ 200 mg/dL achieving MAPE 13.7% and 8%, respectively. These are the first results allowing further development of the solution and achieving better results. One of the limitations of our study was that only 151 people participated in the study, which is a good introduction to research, while a larger population would improve the results. Total cholesterol level values observed in patients have a right skewed distribution and a small number of people achieved results above the norm, which was difficult for the model to generalize; however, the results in the norm range, where the number of patients was higher, show that such prediction is possible, and it is possible to achieve smaller errors with a larger population. One of the disadvantages of our study is that as a method of determining total cholesterol level in blood, we adopted a portable device for a capillary blood test strip and not measurements from venous blood performed in a professional laboratory with venous blood samples. Measurements with such a device are also burdened with measurement errors. Studies and reports show that the mean absolute relative difference of the five cholesterol self-tests ranged from $6 \pm 5\%$ (Accutrend Plus) to $20 \pm 12\%$ (Mylan Mytest).^{52,53} Our study included people who fasted before the test and those who fasted after a meal. Studies show that there are no clinically significant differences in the level of total cholesterol in the blood after fasting and after a meal.⁵⁴ Our method copes with both cases.

Human breath is composed of many compounds that reflect the state of the body but also affect the response of sensors and the prediction of algorithms. Factors that can distort the results include external air pollution,^{12,55} smoking, drinking, or eating immediately before the test. In addition, medications taken or other co-occurring diseases also have an impact. Often, when patients have metabolic syndrome⁵⁶ (as was the case in our studies), a simultaneous increase in blood parameters such as cholesterol, blood glucose level or triglycerides is observed. Therefore, it is important to collect additional data about patients, as well as to determine the patient's behavior before the test, just as is done with standard blood tests.

The next stages of the study development are the development of a portable device that would allow for broader screening of patients in various medical centers and comparison of results with total cholesterol determined in venous blood. One of the possibilities is also the study of additional parameters such as LDL-C and HDL-C levels and an attempt to predict them based on breathing. In summary, our study and the developed e-nose with machine learning algorithms provide a good basis for further research on a larger




Figure 8. Bland-Altman plot of predictions of total cholesterol level in the norm range.

population and the development of a portable device for noninvasive prediction of total cholesterol, HDL-C and LDL-C levels based on a breath sample.

AUTHOR INFORMATION

Corresponding Author

Anna Paleczek – AGH University of Krakow, Faculty of Computer Science Electronics and Telecommunications, Institute of Electronics, Krakow 30-059, Poland; orcid.org/0000-0002-1467-3017; Email: paleczek@agh.edu.pl

Authors

Justyna Grochala – Department of Prosthodontics and Orthodontics, Dental Institute, Faculty of Medicine, Jagiellonian University Medical College, Kraków 31-008, Poland

Dominik Grochala – AGH University of Krakow, Faculty of Computer Science Electronics and Telecommunications, Institute of Electronics, Krakow 30-059, Poland

Jakub Słowik – AGH University of Krakow, Faculty of Computer Science Electronics and Telecommunications, Institute of Electronics, Krakow 30-059, Poland; University Clinical Hospital in Opole, Institute of Medical Sciences, University of Opole, Opole 46-020, Poland

Małgorzata Pihut – Department of Prosthodontics and Orthodontics, Dental Institute, Faculty of Medicine, Jagiellonian University Medical College, Kraków 31-008, Poland

Jolanta E. Loster – Professor Loster's Orthodontics, Private practice, Faculty of Medicine, Jagiellonian University Medical College, Krakow 30-433, Poland

Artur Rydosz – AGH University of Krakow, Faculty of Computer Science Electronics and Telecommunications, Institute of Electronics, Krakow 30-059, Poland; The University Hospital in Krakow, Laboratory of Functional and Virtual Medical 3D Imaging [3D-vFMi(maging)/3D-FM], Krakow 30-688, Poland; orcid.org/0000-0002-9148-1094

Complete contact information is available at: <https://pubs.acs.org/10.1021/acssensors.4c02198>

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. A.P. worked on conceptualization, methodology, investigation, formal analysis, and data curation, software, visualization, writing of original original draft and review and editing. J.G. conducted conceptualization, methodology, and investigation. D.G. performed conceptualization, methodology, and investigation. J.S. helped in writing of the original draft. M.P. conducted conceptualization, methodology, project administration, and supervision. J.E.L. worked on conceptualization, methodology, project administration, and supervision. A.R. performed project administration, conceptualization, methodology, investigation, writing of the original draft, review, and editing, supervision, funding acquisition

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The local ethical committee approved the study protocol (Jagiellonian University KBET: 1072.6120.40.2023). The experiments were conducted in accordance with the Declaration of Helsinki, principles of Good Clinical Practice, and written informed consent was obtained from all participants before participation. The work was supported by the IDUB AGH 4122 grant and the statutory activity at the Institute of Electronics AGH.

ABBREVIATIONS

CVDs, cardiovascular diseases; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; MAE, mean absolute error; MAPE, mean absolute percentage error; ppb, parts per billion; ppm, parts per million; ppt, parts per trillion; RH, relative humidity; RMSE, root mean square error; TC, total cholesterol; VOCs, volatile organic compounds

REFERENCES

- (1) Wang, Z.; Wang, C. Is breath acetone a biomarker of diabetes? A historical review on breath acetone measurements. *J. Breath Res.* **2013**, *7* (3), 037109.
- (2) Neupane, S.; Peverall, R.; Richmond, G.; Blaikie, T. P. J.; Taylor, D.; Hancock, G.; et al. Exhaled breath isoprene rises during

- hypoglycemia in type 1 diabetes. *Diabetes Care* **2016**, *39* (7), No. e97–8.
- (3) Rydosz, A. Diabetes Without Needles: Non-invasive Diagnostics and Health Management [Internet]. *Diabetes Without Needles: Non-invasive Diagnostics and Health Management*. Elsevier; 2022, 1–302. <http://www.sciencedirect.com:5070/book/9780323998871/diabetes-without-needles>.
- (4) Paleczek, A.; Rydosz, A. Review of the algorithms used in exhaled breath analysis for the detection of diabetes. *J. Breath Res.* **2022**, *16* (2), 026003.
- (5) Guida, G.; Carriero, V.; Bertolini, F.; Pizzimenti, S.; Heffler, E.; Paoletti, G.; et al. Exhaled nitric oxide in asthma: from diagnosis to management. *Curr. Opin. Allergy Clin. Immunol.* **2023**, *23* (1), 29–35.
- (6) Xepapadaki, P.; Adachi, Y.; Pozo Beltrán, C. F.; El-Sayed, Z. A.; Gómez, R. M.; Hossny, E.; et al. Utility of biomarkers in the diagnosis and monitoring of asthmatic children. *World Allergy Organization J.* **2023**, *16* (1), 100727.
- (7) Politi, L.; Monasta, L.; Rigrassi, M. N.; Princivale, A.; Gonfiotti, A.; Camiciottoli, G.; Perbellini, L.; et al. Discriminant Profiles of Volatile Compounds in the Alveolar Air of Patients with Squamous Cell Lung Cancer, Lung Adenocarcinoma or Colon Cancer. *Molecules* **2021**, *26* (3), Page 550.
- (8) Ratiu, I. A.; Ligor, T.; Bocos-Bintintan, V.; Mayhew, C. A.; Buszewski, B. Volatile organic compounds in exhaled breath as fingerprints of lung cancer, asthma and COPD. *J. Clin. Med.* **2021**, *10* (1), 32.
- (9) Chung, J.; Akter, S.; Han, S.; Shin, Y.; Choi, T. G.; Kang, I.; Kim, S.; et al. Diagnosis by Volatile Organic Compounds in Exhaled Breath from Patients with Gastric and Colorectal Cancers. *IJMS* **2023**, *24* (1), 129.
- (10) Tortora, G.; Derrickson, B. *Principles of Anatomy and Physiology*. 15th ed. [Internet] ed., Vol. 53, John Wiley & Sons, Inc; 2013, pp. 1689–1699.
- (11) Smolinska, A.; Klaassen, E. M. M.; Dallinga, J. W.; Van De Kant, K. D. G.; Jobsis, Q.; Moonen, E. J. C.; et al. Profiling of volatile organic compounds in exhaled breath as a strategy to find early predictive signatures of asthma in children. *PLoS One* **2014**, *9* (4), 2022.
- (12) Longo, V.; Forleo, A.; Ferramosca, A.; Notari, T.; Pappalardo, S.; Siciliano, P.; et al. Blood, urine and semen volatile organic compound (VOC) pattern analysis for assessing health environmental impact in highly polluted areas in Italy. *Environ. Pollut.* **2021**, *286*, 117410.
- (13) Ferrus, L.; Guenard, H.; Vardon, G.; Varene, P. Respiratory water loss. *Respir Physiol.* **1980**, *39* (3), 367–381.
- (14) Paukner, K.; Lesná, I. K.; Poledne, R. Cholesterol in the Cell Membrane—An Emerging Player in Atherogenesis. *Int. J. Mol. Sci.* **2022**, *23* (1), 533.
- (15) Schade, D. S.; Shey, L.; Eaton, R. P. Cholesterol Review: A Metabolically Important Molecule. *Endocr Pract.* **2020**, *26* (12), 1514–1523.
- (16) Cardiovascular diseases (CVDs). [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)).
- (17) McGill, H. C.; McMahan, C. A.; Gidding, S. S. Preventing heart disease in the 21st century: Implications of the pathobiological determinants of atherosclerosis in youth (PDAY) study. *Circulation* **2008**, *117* (9), 1216–1227.
- (18) Jung, E.; Kong, S. Y.; Ro, Y. S.; Ryu, H. H.; Shin, S. D. Serum Cholesterol Levels and Risk of Cardiovascular Death: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies. *Int. J. Environ. Res. Public Health* **2022**, *19* (14), 8272.
- (19) Deneris, E. S.; Stein, R. A.; Mead, J. F. In vitro biosynthesis of isoprene from mevalonate utilizing a rat liver cytosolic fraction. *Biochem Biophys Res. Commun.* **1984**, *123* (2), 691–696.
- (20) Kushch, I.; Arendacká, B.; stólc, S.; Mochalski, P.; Filipiak, W.; Schwarz, K.; et al. Breath isoprene—aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. *Clin Chem. Lab Med.* **2008**, *46* (7), 1011–1018.
- (21) Stone, B. G.; Besse, T. J.; Duane, W. C.; Dean Evans, C.; DeMaster, E. G. Effect of regulating cholesterol biosynthesis on breath isoprene excretion in men. *Lipids* **1993**, *28* (8), 705–708.
- (22) Sitaula, S.; Burris, T. P. Encyclopedia of Cell Biology/Bradshaw, R. A.; Stahl, P. D., Eds. Vol. 3. *Encyclopedia of Cell Biology*; Elsevier Ltd., 2016.
- (23) Oliveira, L. F. D.; Mallafré-Muro, C.; Giner, J.; Perea, L.; Sibila, O.; Pardo, A.; Marco, S.; et al. Breath analysis using electronic nose and gas chromatography-mass spectrometry: A pilot study on bronchial infections in bronchiectasis. *Clin. Chim. Acta.* **2022**, *526*, 6–13.
- (24) Deng, C.; Zhang, J.; Yu, X.; Zhang, W.; Zhang, X. Determination of acetone in human breath by gas chromatography-mass spectrometry and solid-phase microextraction with on-fiber derivatization. *J. Chromatogr B Analyt Technol. Biomed Life Sci.* **2004**, *810* (2), 269–275.
- (25) Markar, S. R.; Chin, S. T.; Romano, A.; Wiggins, T.; Antonowicz, S.; Paraskeva, P.; et al. Breath Volatile Organic Compound Profiling of Colorectal Cancer Using Selected Ion Flow-tube Mass Spectrometry. *Ann. Surg.* **2019**, *269* (5), 903–910.
- (26) Jung, Y. J.; Seo, H. S.; Kim, J. H.; Song, K. Y.; Park, C. H.; Lee, H. H. Advanced Diagnostic Technology of Volatile Organic Compounds Real Time analysis Analysis From Exhaled Breath of Gastric Cancer Patients Using Proton-Transfer-Reaction Time-of-Flight Mass Spectrometry. *Front. Oncol.* **2021**, *11*, 1368.
- (27) Gilchrist, F. J.; Razavi, C.; Webb, A. K.; Jones, A. M.; Španěl, P.; Smith, D.; et al. An investigation of suitable bag materials for the collection and storage of breath samples containing hydrogen cyanide. *J. Breath Res.* **2012**, *6* (3), 036004.
- (28) Steeghs, M. M. L.; Cristescu, S. M.; Harren, F. J. M.; Woollam, M.; Angarita-Rivera, P.; et al. The suitability of Tedlar bags for breath sampling in medical diagnostic research. *Physiol. Meas.* **2006**, *28* (1), 73.
- (29) Ghimenti, S.; Lomonaco, T.; Bellagambi, F. G.; Tabucchi, S.; Onor, M.; Trivella, M. G.; et al. Comparison of sampling bags for the analysis of volatile organic compounds in breath. *J. Breath Res.* **2015**, *9* (4), 047110.
- (30) Dharmawardana, N.; Goddard, T.; Woods, C.; Watson, D. I.; Ooi, E. H.; Yazbeck, R. Development of a non-invasive exhaled breath test for the diagnosis of head and neck cancer. *Br. J. Cancer* **2020**, *123* (12), 1775–1781.
- (31) Vicent-Claramunt, A.; Naujalis, E. Cheap and easy human breath collection system for trace volatile organic compounds screening using thermal desorption – gas chromatography mass spectrometry. *MethodsX* **2021**, *8*, 101386.
- (32) Hariyanto, S. R.; Wijaya, D. R. Detection of diabetes from gas analysis of human breath using e-nose. In *Vols. 2018-January, Proceedings of the 11th International Conference on Information and Communication Technology and System, ICTS 2017*; Institute of Electrical and Electronics Engineers Inc., 2017, pp. 241–246.
- (33) Gouma, P.; Prasad, A.; Stanacevic, S. A selective nanosensor device for exhaled breath analysis. *J. Breath Res.* **2011**, *5* (3), 037110.
- (34) Güntner, A. T.; Pineau, N. J.; Chie, D.; Krumeich, F.; Pratsinis, S. E. Selective sensing of isoprene by Ti-doped ZnO for breath diagnostics. *J. Mater. Chem. B* **2016**, *4* (32), 5358–5366.
- (35) 3in1 device – PEMPA. <https://pempa.pl/urzadzenie-3w1/>.
- (36) Mochalski, P.; King, J.; Unterkofler, K.; Amann, A. Stability of selected volatile breath constituents in Tedlar, Kynar and Flexfilm sampling bags. *Analyst* **2013**, *138* (5), 1405–1418.
- (37) McGarvey, L. J.; Shorten, C. V. The Effects of Adsorption on the Reusability of Tedlar® Air Sampling Bags. *AIHAJ. - American Industrial Hygiene Association* **2000**, *61* (3), 375–380.
- (38) Beauchamp, J.; Herbig, J.; Gutmann, R.; Hansel, A. On the use of Tedlar® bags for breath-gas sampling and analysis. *J. Breath Res.* **2008**, *2* (4), 046001.
- (39) Zuppa, M.; Distanto, C.; Persaud, K. C.; Siciliano, P. Recovery of drifting sensor responses by means of DWT analysis. *Sens. Actuators, B* **2007**, *120* (2), 411–416.

- (40) Dennler, N.; Rastogi, S.; Fonollosa, J.; van Schaik, A.; Schmuker, M. Drift in a popular metal oxide sensor dataset reveals limitations for gas classification benchmarks. *Sens. Actuators, B* **2022**, *361*, 131668.
- (41) Liu, L.; Li, W.; He, Z. C.; Chen, W.; Liu, H.; Chen, K.; et al. Detection of lung cancer with electronic nose using a novel ensemble learning framework. *J. Breath Res.* **2021**, *15* (2), 026014.
- (42) Polaka, I.; Bhandari, M. P.; Mezmale, L.; Anarkulova, L.; Veliks, V.; Sivins, A. Modular Point-of-Care Breath Analyzer and Shape Taxonomy-Based Machine Learning for Gastric Cancer Detection. *Diagnostics* **2022**, *12* (2), 491.
- (43) Paleczek, A.; Grochala, D.; Rydosz, A. Artificial breath classification using XGBoost algorithm for diabetes detection. *Sensors* **2021**, *21* (12), 4187.
- (44) Binson, V. A.; Subramoniam, M.; Sunny, Y.; Mathew, L. Prediction of Pulmonary Diseases with Electronic Nose Using SVM and XGBoost. *IEEE Sens. J.* **2021**, *21* (18), 20886–20895.
- (45) Paleczek, A.; Rydosz, A. The effect of high ethanol concentration on E-nose response for diabetes detection in exhaled breath: Laboratory studies. *Sens. Actuators, B* **2024**, *408*, 135550.
- (46) Pedregosa, F.; Michel, V.; Grisel Oliviergrisel, O.; Blondel, M.; Prettenhofer, P.; Weiss, R.; et al. Scikit-learn: Machine Learning in Python. *J. Machine Learning Res.* **2011**, *12* (85), 2825–2830.
- (47) Buitinck, L.; Louppe, G.; Blondel, M.; Pedregosa, F.; Müller, A. C.; Grisel, O. et al. *API Design For Machine Learning Software: experiences From The Scikit-Learn Project.* 2013.
- (48) Welcome to LightGBM's documentation! — LightGBM 4.0.0 documentation. <https://lightgbm.readthedocs.io/en/stable/>.
- (49) Cherkassky, V.; Ma, Y. Comparison of model selection for regression. *Neural Comput.* **2003**, *15* (7), 1691–1714.
- (50) Ke, G.; Meng, Q.; Finley, T.; Wang, T.; Chen, W.; Ma, W., et al. LightGBM: A Highly Efficient Gradient Boosting Decision Tree.
- (51) Hammouri, H. M.; Sabo, R. T.; Alsaadawi, R.; Kheirallah, K. A. Handling Skewed Data: A Comparison of Two Popular Methods. *Appl. Sci.* **2020**, *10* (18), 6247.
- (52) Kurstjens, S.; Gemen, E.; Walk, S.; Njo, T.; Krabbe, J.; Gijzen, K.; et al. Performance of commercially-available cholesterol self-tests. *Ann. Clin Biochem.* **2021**, *58* (4), 289–296.
- (53) Suklan, J.; Mutepfa, C.; Dickinson, R.; Hicks, T.; Williams, C.; Nick, H. E. et al. Point of care testing for cholesterol measuring: A rapid review and presentation of the scientific evidence Supporting primary care in the prevention and management of cardiovascular disease.
- (54) Craig, S. R.; Amin, R. V.; Russell, D. W.; Paradise, N. F. Blood cholesterol screening: Influence of fasting state on cholesterol results and management decisions. *J. Gen Intern Med.* **2000**, *15* (6), 395–399.
- (55) Blanchet, L.; Smolinska, A.; Baranska, A.; Tigchelaar, E.; Swertz, M.; Zhernakova, A.; et al. Factors that influence the volatile organic compound content in human breath. *J. Breath Res.* **2017**, *11* (1), 016013.
- (56) Han, T. S.; Lean, M. E. J. Metabolic syndrome. *Medicine* **2015**, *43* (2), 80–87.